Adherence and persistence with medication regimens is highly relevant to disease outcomes.

Slides:

Advertisements

Similar presentations

Defining Adherence and Persistence

Advertisements

ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.

Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema Effect of renin-angiotensin system blockade on calcium.

Innovative Pharmacy Services Jann B. Skelton, RPh, MBA Vice President of Operations MEDICA.

The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure

Digital Health: Connecting Your Medicines to the Internet Means Better Care at Lower Cost George M. Savage, MD Cofounder & Chief Medical Officer May 2,

Networked Health Cody Goldberg. What? Combined network of health devices. Multiple health devices working in tandem. Ingestible/implantable chips. Bluetooth,

Primary care of hypertensive patients and the risk of acute events Irina Stirbu-Wagner Markus MJ Nielen Maaike Langelaan Robert A. Verheij Joke C. Korevaar.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.

Managing Diabetes Medications. Topics What medications are available to –Manage diabetes? –Lower blood pressure? –Improve cholesterol? How can you keep.

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen.

Randomized, double-blind, multicenter, controlled trial.

TRANSLATING VISITS INTO PATIENTS USING AMBULATORY VISIT DATA (Hypertensive patient case study) by Esther Hing, M.P.H. and Julia Holmes, Ph.D U.S. DEPARTMENT.

Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal

Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.

Medication Adherence The following module is designed as a basic overview of medication adherence for providers of healthcare, particularly those in a.

D-1 Pravastatin-Aspirin Combination The Medical Need Thomas A. Pearson, M.D., Ph.D. Albert D. Kaiser Professor of Community & Preventive Medicine University.

Hypertension (High Blood Pressure)

Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.

1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.

10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

Community Pharmacy Adherence Services. Adherence to Prescription Medication Many patients have difficulty taking prescription medications as prescribed.

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

Initial Combination Treatment in Hypertension: Who Are the Candidates George Bakris, MD, F.A.S.H., F.A.S.N. Professor of Medicine Director, Hypertensive.

Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159.

Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.

Federal Study of Adherence to Medications (FAME) Trial Presented at The American Heart Association Annual Scientific Session 2006 Presented by Dr. Allen.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.

Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.

WA2: High Blood Pressure Medicine It can save your life, but can you afford it?

Wise Ones Coli Clements, Megan Kamil, Kerri Spilker.

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Michelle Gardner RN NUR-224. OBJECTIVES  Define normal blood pressure and categories of abnormal pressure  Identify risk factors for hypertension 

JNC 7 血壓分期. 血壓分期 JNC 7 ： 1. 增加高血壓前期 2.Stages 2 及 3 高血壓被合併 JNC 7, 2003.

Dr.AZDAKI (cardiologist).   Initial monotherapy is successful in many patients with mild primary hypertension (formerly called "essential" hypertension).

Guidelines recommend, as first-line treatment for hypertension, a diuretic or the combination of diuretic ± ACE inhibitor. Prevention of Stroke in Patients.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH,

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.

Date of download: 5/30/2016 Copyright © The American College of Cardiology. All rights reserved. From: Peripheral Artery Disease: Evolving Role of Exercise,

Internal Medicine Workshop Series Laos September /October 2009.

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

Resistant Hypertension Topic Discussion Brian Skinner, PharmD PGY-1 Pharmacy Resident St. Vincent Indianapolis Hospital.

Discontinuation of medication after nonfatal event: MI

Copyright © 2007 American Medical Association. All rights reserved.

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

Nat. Rev. Nephrol. doi: /nrneph

The Hypertension in the Very Elderly Trial (HYVET)

Step Care Therapy for Hypertension in Diabetic Patients

So you want to measure adherence…

Table of Contents Why Do We Treat Hypertension? Recommendation 5

Primary Hypertension Max C. Reif, M.D.

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Clinician Referral Training

The Research Question Does changing prescription medication labels to conform to the United States Pharmacopeia (USP) patient-centered, more understandable,

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Medication Adherence: WHO Cares?

Internal Medicine Workshop Series Laos September /October 2009

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

A Single Participant Exposed Twice to an Inflammatory Stimulus

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Presentation transcript:

Adherence and persistence with medication regimens is highly relevant to disease outcomes

Adherence to a medication regimen is generally defined as the extent to which patients take medications as prescribed by their health care provider Osterberg L, Blasche T. N Engl J Med. 2005;353: Breekveldt-Postma NS et al. Curr Med Res Opin. 2008;24: Nonpersistence with antihypertensive therapy is associated with an increased risk of myocardial infarction and stroke. 2 Methods that can be used to confirm adherence to a medication regimen include: monitoring of pill count, monitoring of prescription refill rate, and patient use of “smart” pill bottles, but these are all indirect measures.

* Defined as the total number of days of therapy for medication dispensed/365 days of study follow-up ACE, angiotensin-converting enzyme; CCB, calcium channel blocker; SPC, single-pill combination Gerbino PP, Shoheiber O. Am J Health System Pharm. 2007;64: SPC (ACE inhibitor + CCB) (n=2839) Free combination (ACE inhibitior + CCB) (n=3367) Medication possession ratio (MPR) * P< % 69% 0%20%40%60%80%100% Prescription of a single-pill combination is associated with improved adherence rates compared with free-combination therapy

A new device* approved by the FDA 1 can be included in antihypertensive pills to monitor the adherence to treatment The ingestible sensor is made entirely of ingredients found in food and is activated upon ingestion to transmit a unique number which is captured by an external patch. The ingestible sensor does not require any battery or antenna; it is powered by the contact with stomach fluids. The ingestible sensor can be embedded in a drug product and can be used for directly confirming medication adherence, as part of a networked wellness system. Edible sensor attached directly to a tablet The networked system has already been tested in hypertension and heart failure populations. * The Ingestion Event Marker (IEM), by Proteus Health. 1. FDA approves digestible microchips to be placed in pills. Medscape. August 3, 2012.